Covid 19: Antithrombotic Treatment Options
Learn about the correlation of thromboembolism and Covid-19. Get information on the guidelines to be followed during an antiplatelet treatment / therapy for a Covid-19 patient.
The FDA is yet to approve a cure or vaccine for Covid-19. Doctors, scientists, and researchers are making their contributions through numerous efforts in finding a way to tackle coronavirus once and for all. So far, antibody testing has been the bulk of understanding Covid-19. The data collected through the tests have proved to be valuable in deriving information by combining observational data and clinical trials.
The infection of Covid-19 has been found to correlate to prothrombic state and inflammation. Studies have shown that most Covid-19 patients in ICU have developed thrombotic complications. Ultrasound examinations done by clinicians handling severe Covid-19 cases show that thromboembolic events were pretty high in their cases. Studies done are a single center in the United States on 395 mechanically ventilated patients, had interesting outcomes. Only 29.1% of the patients who had received anticoagulation therapy died, while 62.7% of the patients who did not receive this treatment died. Thus, anticoagulation proved to be beneficial for Covid-19 patients.
There are, however, strict guidelines following antithrombotic therapy.
1. Chronic Anticoagulant and Antiplatelet Therapy
If a patient with an underlying condition that requires antiplatelet therapy is diagnosed with Covid-19, he or she should not stop taking these medications.
2. Venous Thromboembolism Prophylaxis
Unless there is an indication of deep vein thrombosis, anticoagulants should not be administered in a bid to prevent Venous Thromboembolism. VTE prophylaxis treatments for patients hospitalized with Covid-19 should not be different from other hospitalized patients undergoing the same therapy.
When it comes to children, their diagnosis with Covid-19 should not be why a pediatrician prescribes VTE prophylaxis. This therapy is also not recommended for preventing arterial thrombosis in patients that have not been diagnosed with Covid-19.
Patients undergoing this treatment are also not to be routinely discharged. There are FDA approved routines regarding discharging patients with a high risk of VTE and bleeding. The indicators to look out for VTE in a Covid-19 patient include the deterioration of their neurological, pulmonary, and cardiac function. The other sign is the sudden loss of peripheral perfusion in a patient.
Specific doses of anticoagulants are recommended for patients suspected to have a thromboembolic condition at the time of diagnosis of the virus. Pregnant patients with Covid-19 should be handled just like patients with conditions that require anticoagulants. These patients should however be managed with a lot of care. Anticoagulant treatment is also safe for breastfeeding Covid-19 patients as they do not affect the newborn.
Paul Singh, MHA, BA
Covid Antibody Diagnostics™
A Natures Body Wellness Corporation, Lake Mary FL 32746
Find us on Google under Antibody Diagnostics